This is part 1 of a 3-part series on UX in Life Sciences from the Pistoia Alliance UXLS community.
If you’re coming from traditional UX into life sciences, you may think you already understand the rules of the game. But here’s the reality: in this industry, the software is not the product — a life-changing therapy is.
That shift changes everything.
From longer timelines and regulatory complexity to constrained research access and fragmented organizational structures, UX in life sciences operates in a fundamentally different environment. Yet as digital transformation and AI adoption accelerate, the role of UX is becoming more strategic than ever.
What is the article about?
This is the first in a 3-part series from the Pistoia Alliance UX in Life Sciences (UXLS) community exploring how UX operates in one of the most complex and regulated industries.
In this article, we focus on what makes UX in life sciences fundamentally different from other sectors and why those differences matter. We explore how regulatory environments, scientific workflows, and long development cycles reshape UX practice, from research and design to measurement and impact. We also highlight the structural challenges practitioners face, including small teams, organizational change, and industry-wide isolation.
Who should read this?
This series is for UX practitioners, designers, researchers, and digital leaders working in or considering moving into life sciences. It is especially relevant for those navigating complex, regulated environments, as well as leaders responsible for digital transformation, R&D systems, or AI adoption.
If you’re interested in how UX operates when the stakes are higher, timelines are longer, and impact reaches patients, this series is for you.
UX in Life Sciences: What’s Actually Different — and Why It Matters
If you move from general software UX into life sciences, your first surprise might be this: “Product” doesn’t mean the software. In life sciences, the drug is the product. The software is the enablement tool that helps create it.
That shift sounds simple, but it changes almost everything about how UX operates.
In most technology environments, UX shapes the core product experience. Roadmaps are driven by growth and engagement. Iteration cycles are short. Feedback loops are tight. In life sciences, timelines stretch across years. Regulatory frameworks are layered and unavoidable. Decisions involve scientists, clinicians, regulatory specialists, IT, legal, and leadership long before a screen is ever designed.
UX here is less about shipping features quickly and more about shaping complex systems responsibly. That means reducing cognitive load in specialized scientific workflows, designing for auditability and traceability, and connecting digital metrics to pipeline progress or patient outcomes rather than clicks and completion rates.
When the true product is a therapy that may take a decade to reach patients, digital misalignment is not just inconvenient. It is expensive, risky, and slow to correct.
The cost of building solutions before understanding problems
That cost becomes most visible when UX is treated as a downstream activity rather than a strategic one. In life sciences, where lifecycles are long and regulatory stakes amplify early misalignment, the difference between a project mindset and a product mindset is not academic. It is a matter of risk management.
Learn more about that mindset shift in part 2 of this series.
Research under constraint
In many industries, recruiting users for research is relatively straightforward. In life sciences, engaging patients, healthcare professionals, or even internal scientific users can involve compliance reviews, layered approvals, and legal oversight. The domains are highly specialized, the tools often carry years of technical debt, and knowledge sharing across companies is constrained by NDAs.
For practitioners entering the field, this can feel restrictive. A researcher accustomed to scheduling ten user interviews in a week may spend that same week navigating a single approval chain.
Another adjustment is the depth of the domain itself. Existing UX skills remain essential, but life sciences has its own language, processes, and scientific context. Learning the vernacular and understanding the workflows takes time, and newcomers often need a longer ramp-up period before they can fully operate with confidence.
But that friction raises the bar. It demands sharper problem framing, knowing exactly which questions matter most before you get limited access to users. It demands clearer articulation of value, because every study must justify its overhead. And it produces more durable outcomes. The friction is real. So is the opportunity to build credibility through rigor.
Small teams, shifting structures
UX teams in life sciences are frequently small relative to the enterprises they support. Some are centralized, some embedded, many in hybrid models that evolve during restructures. And restructures are common. Reporting lines shift. Priorities change. Budgets tighten.
Practitioners learn to operate through influence rather than authority, adapting to changing contexts while maintaining continuity in user-centered practice. Without shared standards and shared language, UX maturity can reset every time the org chart changes, with years of institutional knowledge and hard-won credibility evaporating in a single reorganization.
The hidden cost of isolation
That fragility is amplified by isolation. Across organizations, practitioners describe remarkably similar experiences: reinventing templates independently, struggling to benchmark maturity, rebuilding momentum after every restructuring, all behind separate walls. Without a sustained community connecting practitioners across organizations, the lessons learned in one team rarely reach another.
Life sciences has a long tradition of pre-competitive collaboration to solve exactly these kinds of shared structural challenges. Communities of practice are how that tradition is extending into UX.
Part 3 of this series explores how communities of practice are taking shape across the industry.
A field worth entering, and a community ready for you
The work can feel slower, more bureaucratic, and demanding of patience and political navigation. Yet it places you at the intersection of science, data, and human experience in ways few industries do. The problems are systemic. The consequences are real. And at the end of the chain, the workflows you improve help bring therapies to patients faster and more reliably. Not many UX roles let you draw a line from your work to someone’s health.
The UX in Life Sciences community within the Pistoia Alliance exists to support this evolution, connecting practitioners across member organizations to exchange frameworks, share lessons, and strengthen the strategic role of UX.
If your organization is already part of the Pistoia Alliance and you are not yet connected to the UXLS community, this is an invitation to join. If your organization is not yet part of Pistoia, that conversation is worth starting. The Alliance supports challenges across data, interoperability, AI, and scientific collaboration well beyond design.
Joining the Pistoia Alliance is a good place to begin: https://pistoiaalliance.org/membership/
If you are outside the industry and curious, the field needs practitioners who understand complexity, not just craft.
UX in life sciences is demanding. It is also becoming more strategic with every digital transformation initiative and every AI investment that depends on human trust and adoption. The practitioners shaping this field do not have to do so in isolation.
What can you do with this?
If you work in UX within life sciences, take a step back and assess where your organization sits: is UX being applied late in delivery, or is it shaping strategy early? The earlier UX is embedded, the greater its impact on reducing risk, aligning stakeholders, and accelerating outcomes.
If you are new to the industry, recognize that success here depends not just on craft, but on navigating complexity, building domain understanding, and influencing across disciplines.
What’s next in this series
In Part 2, we explore how the differences we’ve discussed fundamentally change the way UX teams need to operate, and why a mindset shift is critical in life sciences.
Join the UX in Life Sciences (UXLS) community
The UX in Life Sciences (UXLS) community at the Pistoia Alliance brings together practitioners across organizations to share frameworks, exchange lessons learned, and strengthen the role of UX in a complex and evolving industry.
If your organization is already a member of the Pistoia Alliance, we invite you to get involved in UXLS. If not, this is an opportunity to explore how the Alliance supports collaboration across data, AI, interoperability, and digital transformation in life sciences.
Where to learn more
The UXLS Community of Experts > https://pistoiaalliance.org/community/uxls/
Joining the Pistoia Alliance > https://pistoiaalliance.org/membership/
About the authors
This article reflects the collective expertise of members of the UX in Life Sciences (UXLS) community within the Pistoia Alliance.
The main contributors were Jing Zhang, PhD Jing Z. · Brian Mila · Nicola Marcon · Peter Hummel · Sven Neumeyer · Voula Gkatzidou, PhD · Breac Baker Breac B. · Peter Horvath · Sudha Y. · Farah Egby
With thanks to our Steering Committee — Sven Neumeyer (Novartis) · Simon Fortenbacher (GSK)· David Pace (Merck) — and to all members of the UXLS Best Practices workstream for their contributions, ideas, and energy throughout the year.